Knockdown of HMGB1 Suppresses Hypoxia-Induced Mitochondrial Biogenesis in Pancreatic Cancer Cells
Open Access
- 1 February 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 13, 1187-1198
- https://doi.org/10.2147/OTT.S234530
Abstract
Purpose: To explore the regulatory effect of HMGB1 upon hypoxia-induced mitochondrial biogenesis in pancreatic cancer PANC1/CFPAC1 cells. Methods: After a down-regulation of HMGB1 expression by lentivirus-mediated RNAi, the effect of knocking down HMGB1 on hypoxia-induced mitochondrial biogenesis was examined. NRF-1/TFAM expression, mtDNA copy number, ATP content and mitochondrial number/morphology in hypoxia-treated pancreatic cancer cells were detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blot, mtDNA and ATP assay kits and electron microscopy, respectively. Cell proliferation was measured by MTS assay. And protein and acetylation levels of PGC-1α and SIRT1 activity were detected by Western blot, immunoprecipitation (IP) and SIRT1 activity kit. Results: Hypoxia enhanced the expressions of NRF-1/TFAM, boosted mtDNA copy number and ATP content and increased the number of mitochondria in pancreatic cancer cells while induction was suppressed by a knockdown of HMGB1. Knocking down HMGB1 expression lowered hypoxia-induced PGC-1α/SIRT1 expression and activity, phosphorylation of AMPK. PGC-1α over-expression by a plasmid transfection failed to boost mtDNA copy number or ATP content in HMGB1-knockdown cells. A knockdown of HMGB1 attenuated hypoxia with AICAR (an AMPK activator)-induced expression of NRF-1, TFAM, PGC-1α, SIRT1 and the proteins of complexes Ⅰ& Ⅲ and reduced the acetylation level of PGC-1α/SIRT1 activity. Additionally, SRT1720 (a SIRT1 activator)-induced elevation in SIRT1 activity boosted hypoxia-induced PGC-1α deacetylation, except in HMGB1-knockdown cells. Conclusion: As a novel regulator of mitochondrial biogenesis via AMPK/SIRT1 pathway under hypoxia, HMGB1 may become a potential drug target for therapeutic interventions in pancreatic cancer.Keywords
This publication has 41 references indexed in Scilit:
- Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancerCell Research, 2017
- Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in ratsBrain Research Bulletin, 2016
- Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial functionNature, 2014
- Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1α signalingOncotarget, 2014
- HMGB1 Promotes Drug Resistance in OsteosarcomaCancer Research, 2012
- High-Mobility Group Box 1 Is Essential for Mitochondrial Quality ControlCell Metabolism, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cellsLeukemia, 2010
- High-mobility group box 1 and cancerBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- CROSSTALK BETWEEN NUCLEAR AND MITOCHONDRIAL GENOMESAnnual Review of Biochemistry, 1996